BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MBL International Introduces TransFix™ a Cellular Stabilization Agent


3/1/2013 9:30:24 AM

WOBURN, Mass., Feb. 28, 2013 /PRNewswire/ -- MBL International (MBLI), a leading life science company, announced today the launch of TransFix. It is a patented cellular stabilization reagent that when added to whole blood, cerebrospinal fluid (CSF), bone marrow and fine needle aspirates, preserves cell surface antigens at room temperature for a minimum of 10 days.

TransFix was developed by scientists in the UK to stabilize blood samples for immunological analysis. Without TransFix­ stabilization, whole blood samples have a transportation and storage shelf life of only 36 hours. Following stabilization, TransFix samples can be stored up to 10 days, saving time and money. TransFix is capable of stabilizing a wide range of body fluids and tissue, including blood, CSF and bone marrow from both human and animal origins. This enables immunological samples to be grouped and stored as well as transported safely.

TransFix incorporates a patented technology developed by Cytomark, a UK Biotechnology Company formed to bring to market blood stabilization technology developed by UK NEQAS. TransFix is now available to North America, South America and Japanese markets.

"MBL International is excited about adding TransFix to our growing portfolio of life sciences products," said Christopher Hargadon, VP of Sales and Marketing at MBL International Corporation. "This technology offers many benefits to researchers in the biotechnology, biopharma, clinical and animal research fields by offering a ready-to-use biological fluid preservative."

The CEO of Cytomark, Dr. Tim Almond, is pleased to announce a new and exclusive distribution agreement with MBL International in the USA. At a recent press conference Dr. Almond said, "We are both pleased and excited that MBL International has agreed to partner with Cytomark in the USA. This is a key step in our international strategy to promote TransFix­. We are confident that MBL International will enable us to reach our strategic goals."

About MBL International Corporation
MBL International Corporation is a leading life science company focused on providing high quality products and solutions for life science research and clinical diagnostics. Their products are used widely in academic research institutions, pharmaceutical and biotechnology companies, government agencies, as well as hospital and reference laboratories. MBL International provides a consultative approach, superior technical and customer support, and convenient purchasing options. For more information, please visit mblintl.com or call 1-781-939-6964.

About Cytomark
Cytomark is a Division of Caltag Medsystems Ltd., based in Buckingham, UK (+44 (0)1280 827460 or office@caltagmedsystems.co.uk). Cytomark was formed in 2005 to bring technologies developed by UK NEQAS to the open market. TransFix was developed by UK NEQAS to facilitate the safe transfer of blood samples in support of their Quality assurance program. Cytomark took an exclusive license for this technology in 2005. The company now has distributors in over 30 countries.

SOURCE MBL International Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES